In this article, we will look at the 13 Best Healthcare Stocks to Buy Under $10.
How Should Investors Act Going Into H2 2025?
On June 27, Tiffany McGhee, CEO of Pivotal Advisors, appeared on CNBC to talk about the best course of action for investors amid current market dynamics. She said that going into the second half of 2025 is a great time for investors to review allocations, trim what’s hot, and reinforce underweight areas to remain aligned with long-term goals. She further stated that diversification remains the best defense against uncertainty and the best offense for what’s next in the market.
READ ALSO: 13 Cheap Healthcare Stocks with Huge Upside Potential and 10 Cheap Large Cap Stocks to Buy According to Hedge Funds.
Meghan Shue, Head of Investment Strategy at Wilmington Trust, also gave her opinion in the same interview, stating that while the market may see some choppiness into the summer, investors should stay invested, as there is a considerable opportunity in the tech sector and also some of the other more beaten-up sectors, including parts of healthcare, which has been a part of the market that nobody has really wanted to touch.
McGhee corroborated this statement, saying that she expects the healthcare sector to offer catch-up opportunities. With these trends in view, let’s look at the 13 best healthcare stocks to buy under $10.
A smiling healthcare professional, treating a patient with the PLEX platform.
Our Methodology
We used Finviz to make a list of the best healthcare stocks priced at less than $10 and chose the top 13 with the highest number of hedge fund holders as of Q1 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund sentiment.
Note: All data was recorded on July 10.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
13 Best Healthcare Stocks to Buy Under $10
13. Organon & Co. (NYSE:OGN)
Stock Price: $9.95
Number of Hedge Fund Holders: 28
Organon & Co. (NYSE:OGN) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 7, Organon & Co. (NYSE:OGN) announced that its VTAMA (tapinarof) cream, 1%, attained a strong recommendation in the American Academy of Dermatology’s (AAD) 2025 focused guideline update for the management of adults with moderate to severe atopic dermatitis (AD).
Organon & Co. (NYSE:OGN) stated that the recommendation highlights the cream’s status as a steroid-free and effective option for daily disease management. It does not have precautions or label warnings, no restrictions on use duration or percentage of body surface area affected, and no contraindications.
Organon & Co. (NYSE:OGN) is a global pharmaceutical company that develops and delivers innovative health solutions via a portfolio of prescription therapies within women’s health, established brands, and biosimilars.
12. MannKind Corporation (NASDAQ:MNKD)
Stock Price: $3.82
Number of Hedge Fund Holders: 29
MannKind Corporation (NASDAQ:MNKD) is one of the 13 Best Healthcare Stocks to Buy Under $10. On May 8, Wells Fargo analyst Tiago Fauth maintained a Buy rating on MannKind Corporation (NASDAQ:MNKD) and set a price target of $9.00.
The rating was based on the company’s promising growth potential and strategic advancements, as it is making notable progress in its MNKD-101 program, according to the analyst. With a majority of the expected sites activated and patients randomized, the interim analysis is set for mid-2026. The analyst expects the MNKD-101 program to advance in the second half of 2025.
Fauth also reasoned that MannKind Corporation (NASDAQ:MNKD) has strong revenue growth, supported by a potential expansion of Afrezza into the pediatric market and Tyvaso DPI royalties. When combined with the market’s focus on tangible revenue streams, these factors justify the analyst’s optimistic rating.
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that develops and commercializes innovative therapeutic devices and products that address serious unmet medical needs for endocrine and orphan lung diseases. The company’s pipeline and products include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.
11. GoodRx Holdings, Inc. (NASDAQ:GDRX)
Stock Price: $4.89
Number of Hedge Fund Holders: 30
GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the 13 Best Healthcare Stocks to Buy Under $10. On June 13, Leerink Partners analyst Michael Cherny maintained a bullish stance on GoodRx Holdings, Inc. (NASDAQ:GDRX), giving the stock a Buy rating with a $7 price target.
The analyst based the rating on the company’s potential for growth and strategic expansion. He stated that GoodRx Holdings, Inc. (NASDAQ:GDRX) is leveraging its elaborate consumer market reach through the introduction of a subscription service for erectile dysfunction medications Sildenafil and Tadalafil at competitive price points.
The analyst considers this move to be a promising expansion, aligning with the company’s mission to slash out-of-pocket expenses for customers. Cherny further stated that GoodRx Holdings, Inc. (NASDAQ:GDRX) holds a significant opportunity to boost its market standing under new leadership, especially through its telehealth capabilities, which have historically been underutilized.
Although he does not guarantee immediate success, the analyst believes that this strategic direction may result in a considerable broadening of GoodRx Holdings, Inc.’s (NASDAQ:GDRX) business beyond its core prescription transactions. The firm thus sees the company’s expansion into subscription services as an innovative step that may differentiate it in the competitive digital health market.
GoodRx Holdings, Inc. (NASDAQ:GDRX) offers a consumer-focused digital healthcare platform that provides free consumer access to convenient medical provider consultations through telehealth, reduced prices for brand and generic medications, and extensive healthcare research and information.
10. Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
Stock Price: $8.39
Number of Hedge Fund Holders: 30
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the 13 Best Healthcare Stocks to Buy Under $10. On June 12, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced the FDA approval of prednisolone acetate ophthalmic suspension, with launch planned for Q3 2025.
Prednisolone acetate ophthalmic suspension, USP 1% is a topical, sterile anti-inflammatory agent for ophthalmic use and treatment of steroid-responsive ocular inflammation.
Andy Boyer, Executive Vice President and Chief Commercial Officer, Affordable Medicines, stated that the Affordable Medicines portfolio is growing continuously, with a diverse and strong pipeline supporting “broader access to high-quality treatments across the US healthcare system.”
Boyer also stated that the prednisolone acetate ophthalmic suspension is a complex product to manufacture and develop, and its approval reflects the quality of Amneal Pharmaceuticals, Inc.’s (NASDAQ:AMRX) R&D capabilities and the strength of its supply and manufacturing operations.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is a medicine company that develops pharmaceuticals, with a product portfolio spanning specialty, generics, biosciences, and product catalog. Its operations are divided into the Generics, Specialty, and AvKARE segments.
9. Bausch Health Companies Inc. (NYSE:BHC)
Stock Price: $6.63
Number of Hedge Fund Holders: 31
Bausch Health Companies Inc. (NYSE:BHC) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 9, Bausch Health Companies Inc. (NYSE:BHC), Canada, announced the availability of CABTREO gel 1.2% w/w, 0.15% w/w, and 3.1% w/w to beneficiaries of the public drug plans of Nova Scotia and Ontario.
The gel, which treats acne vulgaris, would also be available through the federal government’s Non-Insured Health Benefits drug plan for Indigenous populations and that of the Correctional Service of Canada.
CABTREO treats acne vulgaris in patients aged 12 and older, and is the first and only triple-combination topical treatment for acne that is approved by Health Canada. It has three action mechanisms as an antibiotic, a retinoid, and an antibacterial agent.
Bausch Health Companies Inc. (NYSE:BHC) develops, manufactures, and markets a range of generic, branded, and branded generic pharmaceuticals, over-the-counter products, and medical devices. The company operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb.
8. Teladoc Health, Inc. (NYSE:TDOC)
Stock Price: $8.86
Number of Hedge Fund Holders: 33
Teladoc Health, Inc. (NYSE:TDOC) is one of the 13 Best Healthcare Stocks to Buy Under $10. Bank of America Securities analyst Allen Lutz reiterated a Hold rating on Teladoc Health, Inc. (NYSE:TDOC) on July 3 with a price target of $8.75, justifying it with the company’s current and future performance.
The analyst reasoned that Teladoc Health, Inc. (NYSE:TDOC) is experiencing a growth slowdown, especially in its Livongo and BetterHelp segments, which underwent a drop in app downloads and monthly active users. Lutz attributed this deceleration to a rise in customer acquisition costs and a cautious consumer spending environment.
However, the analyst also acknowledged that Teladoc Health, Inc.’s (NYSE:TDOC) recent acquisitions, Catapult and Uplift, are paving the way for future revenue growth despite these challenges.
Lutz further stated that these initiatives are in their early stages and would require time to materialize. Similarly, other strategic initiatives, such as international expansion and insurance coverage, will also take time to make an impact, according to the analyst, supporting the cautious near-term outlook and potential for long-term growth.
Teladoc Health, Inc. (NYSE:TDOC) provides virtual healthcare services and operates through two segments: BetterHelp and Teladoc Health Integrated Care. The BetterHelp sector covers its direct-to-consumer (D2C) mental health platform.
Teladoc Health Integrated Care comprises a range of global virtual medical services, including specialty medical, expert medical services, general medical, mental health, chronic condition management, and more.
7. Clover Health Investments, Corp. (NASDAQ:CLOV)
Stock Price: $3.10
Number of Hedge Fund Holders: 33
Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 9, Clover Health Investments, Corp. (NASDAQ:CLOV) announced the launch of a new community-based pharmacy pilot program across New Jersey, built in partnership with IPC Digital Health.
The initiative aims to help seniors in managing their medications and improve their health at home, supported by the local pharmacies they trust and know.
Clover Health Investments, Corp. (NASDAQ:CLOV) stated that IPC’s iCare+ Independent Pharmacy Network would anchor the program, which covers thousands of community-rooted pharmacies across the nation and several in New Jersey.
Leveraging virtual services and innovative care tools, these local pharmacies would eliminate the need for unnecessary hospital visits by helping Clover members living with chronic conditions manage and stay on track with their medications.
Clover Health Investments, Corp. (NASDAQ:CLOV) is a physician enablement technology company that offers Medicare Advantage plans in the United States. It offers PPO and HMO Medicare Advantage plans in several US states.
6. Brookdale Senior Living Inc. (NYSE:BKD)
Stock Price: $7.55
Number of Hedge Fund Holders: 34
Brookdale Senior Living Inc. (NYSE:BKD) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July 8, Ben Hendrix from RBC Capital maintained a Buy rating on Brookdale Senior Living Inc. (NYSE:BKD) with a price target of $9.00.
In its June report, Brookdale Senior Living Inc. (NYSE:BKD) reported a notable improvement in its occupancy rates for the month, with a weighted average occupancy of 80.5%. This marks a rise of 230 basis points year-over-year and 50 basis points sequentially.
The company also reported that the month-end consolidated occupancy reached 82.2%, suggesting effective sales execution and strong demand. These trends highlight the company’s standing in the senior living industry.
Brookdale Senior Living Inc. (NYSE:BKD) operates senior living communities. The company focuses on assisted living, dementia-care communities, independent living, and continuing care retirement centers. Its operations are divided into the Independent Living, Assisted Living and Memory Care, and CCRCs segments.
5. Wave Life Sciences Ltd. (NASDAQ:WVE)
Stock Price: $7.83
Number of Hedge Fund Holders: 38
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 4, analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on Wave Life Sciences Ltd. (NASDAQ:WVE), retaining the price target of $24.00.
The analyst supported the rating with the company’s promising developments in RNA editing, especially in the treatment for alpha-1-antitrypsin deficiency (AATD). He reasoned that the initial human data for the company’s WVE-006 compound exhibited optimistic results, as patients reached notable levels of AAT protein after a single low dose.
According to Schwartz, this breakthrough marks a significant milestone for Wave Life Sciences Ltd. (NASDAQ:WVE) while also setting a precedent for the broader RNA editing domain. He expects the upcoming data readouts to have further positive outcomes and anticipates a dose-dependent rise in efficacy with an increase in dosage.
The analyst also stated that the potential to exceed the established 11 µM threshold for AAT protein, and even approach normal healthy levels, may cause a considerable boost to the stock’s value.
Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology company that develops and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. PRISM combines a deep understanding of human genetics with chemistry innovation and multiple modalities for scientific discoveries and breakthroughs that treat prevalent and rare disorders.
4. BioCryst Pharmaceutical Inc. (NASDAQ:BCRX)
Stock Price: $8.92
Number of Hedge Fund Holders: 43
BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 7, RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) and set a price target of $13.00.
The same day, the company also announced the appointment of Babar Ghias as Chief Financial Officer and Head of Corporate Development.
With extensive experience from his prior roles at AvenCell Therapeutics and Paragon Biosciences, the company expects his appointment to bolster BioCryst Pharmaceutical Inc.’s (NASDAQ:BCRX) leadership team and support its goals of growth acceleration and increase in value creation.
Management also sees this strategic move as instrumental for BioCryst Pharmaceutical Inc.’s (NASDAQ:BCRX) financial discipline and operational excellence, supporting its optimistic growth plans.
BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) is a biotechnology company that provides structure-guided drug design to develop oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases.
3. Dyne Therapeutics, Inc. (NASDAQ:DYN)
Stock Price: $8.78
Number of Hedge Fund Holders: 46
Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July 7, Luca Issi from RBC Capital maintained a Buy rating on Dyne Therapeutics, Inc. (NASDAQ:DYN) with a price target of $25.00.
In other news, Dyne Therapeutics, Inc. (NASDAQ:DYN) announced on June 30 that it entered into a $275 million non-dilutive senior secured term loan facility with Hercules Capital. The company expects the transaction to bolster its balance sheet as it continues with DYNE-101 and DYNE-251 through critical clinical and regulatory milestones, for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), respectively.
John Cox, president and chief executive officer of Dyne, stated that the company is well-positioned to execute its plans to deliver functional improvement to the neuromuscular community, supported by “$100 million funded upfront and access to additional capital aligned with clinical, regulatory, and commercial progress.” Dyne Therapeutics, Inc. (NASDAQ:DYN) is also nearing a potential US launch in DMD in 2027.
Dyne Therapeutics, Inc. (NASDAQ:DYN) develops innovative life-transforming therapies for genetically driven muscle diseases. The company has a brand portfolio for muscle diseases, including facioscapulohumeral muscular dystrophy, myotonic dystrophy type 1, and Duchenne muscular dystrophy.
2. Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Stock Price: $6.42
Number of Hedge Fund Holders: 47
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the 13 Best Healthcare Stocks to Buy Under $10. On May 1, analyst Ritu Baral from TD Cowen maintained a Buy rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD), keeping the price target at $20.00.
The analyst based the rating on the company’s future growth potential and strategic positioning, stating that Amicus Therapeutics, Inc. (NASDAQ:FOLD) has maintained a positive outlook for GAAP profitability in H2 2025.
This trend emerged despite the Q1 revenue misses for both PomOp and Galafold, which were affected by higher UK VPAG rebates. Baral thus reasoned that these trends suggest confidence in the company’s operations and its ability to manage costs and drive future profitability.
Another factor supporting the analyst’s positive rating is Amicus Therapeutics, Inc.’s (NASDAQ:FOLD) pipeline expansion, especially with the in-licensing of DMX-200 for FSGS. This highlights the company’s commitment to boosting its long-term growth prospects and expanding its product offerings, according to Baral.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) discovers, develops, and delivers medicines to treat metabolic diseases. Its product portfolio includes the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.
1. Viatris Inc. (NASDAQ:VTRS)
Stock Price: $9.23
Number of Hedge Fund Holders: 49
Viatris Inc. (NASDAQ:VTRS) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on June 30, Goldman Sachs reiterated a Hold rating on Viatris Inc. (NASDAQ:VTRS) with a price target of $10.00.
The company reported $3.3 billion in total revenues in fiscal Q1 2025, down 11% on a reported basis and down 2% on a divestiture-adjusted operational basis as compared to the same period last year. This drop was primarily attributed to the negative Indore Impact.
Management stated that if the Indore Impact is excluded, total revenues would have increased 2% on a divestiture-adjusted operational basis compared to fiscal Q1 2024.
Viatris Inc. (NASDAQ:VTRS) also generated around $67 million in new product revenues in fiscal Q1 2025, and expects to deliver new product revenues in 2025 in the $450 million to $550 million range.
Viatris Inc. (NASDAQ:VTRS) is a global healthcare company that provides healthcare and pharmaceutical products. The company’s medicines and treatments span various therapeutic areas, including oncology, cardiovascular, dermatology, immunology, eye care, gastroenterology, and women’s healthcare. Its operations are divided into the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
While we acknowledge the potential of VTRS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VTRS and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
